Whalegun
List

USTR Announces Initiation of Section 301 Investigation of Germany’s Persistent Underpayment for Innovative Pharmaceutical Products

USTR noticeInvestigation openedPublished 06/18Open the original

Summary

USTR Jamieson Greer initiates a Section 301 investigation into whether Germany's persistent underpayment for innovative pharmaceutical products is unreasonable or discriminatory and burdens U.S. commerce. Written comments are due by August 10, 2026, and a hearing will be held on September 22, 2026.

By industry

Day by day after the announcement

Healthcare & Drug Pricing stocks and the S&P 500 after the announcement, cumulative %
Healthcare & Drug Pricing stocks and the S&P 500 after the announcement, cumulative %
DayHealthcare & Drug Pricing stocksS&P 500
26/06/170.0%0.0%
26/06/18−1.7%+0.6%
26/06/22−0.5%+0.1%
26/06/23+0.9%−1.1%
26/06/24+0.9%−0.7%
26/06/25+2.0%−1.2%
26/06/26+4.3%−1.6%
26/06/29+4.1%−0.3%
26/06/30+3.5%+0.4%
26/07/01+4.1%+0.3%
26/07/02+6.4%+0.2%
26/07/06+4.8%+1.2%
26/07/07+7.0%+0.6%
26/07/08+6.6%+0.3%
26/07/09+5.9%+1.2%
26/07/10+5.3%+1.7%
26/07/13+6.4%+0.8%
26/07/14+5.0%+1.2%
26/07/15+4.2%+1.6%
26/07/16+5.9%+1.0%
26/07/17+5.9%0.0%

Korean stocks in these industries

  • Samsung Biologics 207940
  • Celltrion 068270
  • SK Biopharmaceuticals 326030

Trades in these industries around the announcement

Members' and insiders' trades in the industries' stocks, 30 days before to 30 days after.

  • Dermot Mark Durcan

    BuyCencora

    $1.1M

    Filed 06/22

  • Dermot Mark Durcan

    BuyCencora

    $1.1M

    Filed 05/28

  • Lauren M. Tyler

    BuyCencora

    $148.6K

    Filed 06/24

  • Larry Robbins

    SellCVS Health

    $187.3M

    Filed 05/21

  • Larry Robbins

    SellCVS Health

    $74.6M

    Filed 05/21

  • Larry Robbins

    SellCVS Health

    $34.6M

    Filed 05/21

  • John Boozman

    BuyUnitedhealth Group

    $1K–$15K

    Reported 07/13

  • Kathryn E. Wengel

    SellJohnson & Johnson

    $2.4M

    Filed 06/12

  • Larry Robbins

    SellCVS Health

    $14.5M

    Filed 05/21

  • Daniel Patrick O'Day

    Sell10b5-1 planGilead Sciences

    $1.4M

    Filed 06/02

  • Tommy Tuberville

    Full salePfizer

    $15K–$50K

    Reported 07/16

  • Brian S. Tyler

    Sell10b5-1 planMcKesson

    $6.6M

    Filed 06/18

  • Larry Robbins

    SellCVS Health

    $6.4M

    Filed 05/21

  • Daniel Patrick O'Day

    Sell10b5-1 planGilead Sciences

    $404.9K

    Filed 06/02

  • Andrew D. Dickinson

    Sell10b5-1 planGilead Sciences

    $376.2K

    Filed 06/16

  • Brian S. Tyler

    Sell10b5-1 planMcKesson

    $3.8M

    Filed 06/11

  • Thomas Kean

    Partial saleJohnson & Johnson

    $1K–$15K

    Reported 07/15

  • Thomas Kean

    Partial saleJohnson & Johnson

    $1K–$15K

    Reported 07/15

  • Rick Larsen

    BuyMcKesson

    $1K–$15K

    Reported 07/12

  • Ilya Yuffa

    Sell10b5-1 planELI Lilly

    $2.9M

    Filed 06/11